SIT PHARMA acquires OSTIDIL-D3 and KEFORAL
SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL
SIT Pharma acquires DERINOX® for France market
SIT Pharma is pleased to announce the acquisition of DERINOX® from Therabel Lucien Pharma Sas
SIT Pharma acquires MIZOLLEN® for France market
SIT Pharma is pleased to announce the acquisition of MIZOLLEN® from THERABEL HEALTHCARE LIMITED
SIT Pharma appears on Il Sole 24 Ore!
SIT Pharma was mentioned by the prestigious business publication “Il Sole 24 Ore” in its 18 April 2025 edition, in a space dedicated to outstanding companies in the Pavia area.
SIT Pharma acquires DINTOINA
SIT Pharma is pleased to announce the acquisition of DINTOINA brand.
The product is indicated for generalized epilepsy control, excluding petit mal and partial seizures.
SIT cooperates with local primary schools
On this occasion, together with students and teachers, we played on the themes of peace, inclusion and active citizenship.
A Passion For Pharmaceuticals
The European Business magazine interviewed Lamberto Pedrotti, Managing Director of SIT Group.
Ambient Marketing Fomentil 2019
The Ambient Marketing Fomentil has begun in Turin, Milan e Pavia.
Advertising Rino Calyptol “Primavera” 2019
The advertising campaign of Rino Calyptol will be live in April.
Laboratorio Farmaceutico Sit Supporting Women With #Sostengo
#sostenGO is an initiative to support female entrepreneurship, promoted by SIT Group since 2017.